The North America Self-monitoring Blood Glucose Devices Market was valued at USD 7.6 billion in 2024 and is estimated to grow at a CAGR of 11.6% to reach USD 22.2 billion by 2034.
This upward trend is driven by a rising number of individuals being diagnosed with diabetes, increasing investments in healthcare infrastructure, and continuous technological progress in blood glucose monitoring solutions. As diabetes becomes more prevalent across the region, there is a growing demand for efficient and accessible ways to track glucose levels. Self-monitoring blood glucose devices allow patients to measure their blood sugar in real time, which supports effective management of their condition and reduces the likelihood of complications. These tools are especially useful for adjusting daily lifestyle habits, medication routines, and diet decisions, offering autonomy and immediate feedback to users. The growth is also supported by a healthcare ecosystem increasingly focused on prevention and proactive disease management, along with greater availability of digital tools that enhance device connectivity, usability, and data interpretation.
Improvements in device precision, ease of use, and digital connectivity have completely transformed how patients engage with diabetes care. Features such as seamless Bluetooth syncing, compact form factors, and integration with smartphone health platforms are making these devices more user-friendly and widely accessible. These advancements are increasing adherence and improving patient outcomes. Real-time data sharing also supports better communication between patients and providers, allowing for timely interventions and personalized care adjustments.
The self-monitoring blood glucose meters segment generated USD 3.3 billion in 2024 and is forecasted to reach USD 10.1 billion by 2034. These meters remain at the core of diabetes management due to their reliability, affordability, and ability to deliver instant results without requiring a clinical setting. Their simple operation allows users to track glucose levels from any location, supporting better self-management of diabetes and contributing to more consistent glycemic control.
The type 2 diabetes segment held a 69.4% share and is expected to reach USD 15.6 billion by 2034. This chronic condition is primarily associated with the body’s reduced sensitivity to insulin or an inability to produce sufficient insulin. While traditionally more common in adults over the age of 45, the condition is increasingly being diagnosed in younger individuals, driven by lifestyle changes and rising obesity rates. Frequent glucose monitoring is critical for type 2 diabetes patients, especially those using medications that could lead to hypoglycemia.
U.S. Self-monitoring Blood Glucose Devices Market was valued at USD 7 billion in 2024. This steady progression is closely linked to increasing investments in healthcare technologies and efforts to make these devices more affordable and widely accessible. As a result, more individuals are incorporating SMBG tools into their daily routines, which is accelerating adoption across the nation.
Several leading companies in the North America Self-monitoring Blood Glucose Devices Market are Sanofi, All Medicus, Sinocare, Ypsomed Holding, Nova Biomedical, Bionime Corporation, LifeScan, Omnis Health, DarioHealth, F. Hoffmann-La Roche, Ascensia Diabetes Care Holdings, B. Braun Melsungen, AgaMatrix, Abbott Laboratories, Arkray, and Teva Pharmaceutical. These players are significantly shaping the competitive landscape through continuous innovation and strategic expansion. Key players in the Self-Monitoring Blood Glucose Devices Market are leveraging a mix of product innovation, digital integration, and strategic partnerships to reinforce their positions. Many companies are introducing compact, connected glucose meters with Bluetooth and app support, aiming to enhance patient engagement and real-time tracking. Some firms focus on integrating SMBG devices with broader chronic care platforms, enabling seamless data sharing with healthcare providers. Expansion into underserved markets and direct-to-consumer models is also gaining traction to boost adoption.
This product will be delivered within 2-4 business days.
This upward trend is driven by a rising number of individuals being diagnosed with diabetes, increasing investments in healthcare infrastructure, and continuous technological progress in blood glucose monitoring solutions. As diabetes becomes more prevalent across the region, there is a growing demand for efficient and accessible ways to track glucose levels. Self-monitoring blood glucose devices allow patients to measure their blood sugar in real time, which supports effective management of their condition and reduces the likelihood of complications. These tools are especially useful for adjusting daily lifestyle habits, medication routines, and diet decisions, offering autonomy and immediate feedback to users. The growth is also supported by a healthcare ecosystem increasingly focused on prevention and proactive disease management, along with greater availability of digital tools that enhance device connectivity, usability, and data interpretation.
Improvements in device precision, ease of use, and digital connectivity have completely transformed how patients engage with diabetes care. Features such as seamless Bluetooth syncing, compact form factors, and integration with smartphone health platforms are making these devices more user-friendly and widely accessible. These advancements are increasing adherence and improving patient outcomes. Real-time data sharing also supports better communication between patients and providers, allowing for timely interventions and personalized care adjustments.
The self-monitoring blood glucose meters segment generated USD 3.3 billion in 2024 and is forecasted to reach USD 10.1 billion by 2034. These meters remain at the core of diabetes management due to their reliability, affordability, and ability to deliver instant results without requiring a clinical setting. Their simple operation allows users to track glucose levels from any location, supporting better self-management of diabetes and contributing to more consistent glycemic control.
The type 2 diabetes segment held a 69.4% share and is expected to reach USD 15.6 billion by 2034. This chronic condition is primarily associated with the body’s reduced sensitivity to insulin or an inability to produce sufficient insulin. While traditionally more common in adults over the age of 45, the condition is increasingly being diagnosed in younger individuals, driven by lifestyle changes and rising obesity rates. Frequent glucose monitoring is critical for type 2 diabetes patients, especially those using medications that could lead to hypoglycemia.
U.S. Self-monitoring Blood Glucose Devices Market was valued at USD 7 billion in 2024. This steady progression is closely linked to increasing investments in healthcare technologies and efforts to make these devices more affordable and widely accessible. As a result, more individuals are incorporating SMBG tools into their daily routines, which is accelerating adoption across the nation.
Several leading companies in the North America Self-monitoring Blood Glucose Devices Market are Sanofi, All Medicus, Sinocare, Ypsomed Holding, Nova Biomedical, Bionime Corporation, LifeScan, Omnis Health, DarioHealth, F. Hoffmann-La Roche, Ascensia Diabetes Care Holdings, B. Braun Melsungen, AgaMatrix, Abbott Laboratories, Arkray, and Teva Pharmaceutical. These players are significantly shaping the competitive landscape through continuous innovation and strategic expansion. Key players in the Self-Monitoring Blood Glucose Devices Market are leveraging a mix of product innovation, digital integration, and strategic partnerships to reinforce their positions. Many companies are introducing compact, connected glucose meters with Bluetooth and app support, aiming to enhance patient engagement and real-time tracking. Some firms focus on integrating SMBG devices with broader chronic care platforms, enabling seamless data sharing with healthcare providers. Expansion into underserved markets and direct-to-consumer models is also gaining traction to boost adoption.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Country, 2021-2034 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
The key companies profiled in this North America Self-monitoring Blood Glucose Devices market report include:- Abbott Laboratories
- AgaMatrix
- All Medicus
- Arkray
- Ascensia Diabetes Care Holdings
- B. Braun Melsungen
- Bionime Corporation
- DarioHealth
- F. Hoffmann-La Roche
- LifeScan
- Nova Biomedical
- Omnis Health
- Sanofi
- Sinocare
- Ypsomed Holding
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 105 |
| Published | September 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 7.6 Billion |
| Forecasted Market Value ( USD | $ 22.2 Billion |
| Compound Annual Growth Rate | 11.6% |
| Regions Covered | North America |
| No. of Companies Mentioned | 15 |
